Base de datos - (CIANE)

Presentación de esta base de datos documental (Sitio web de CIANE)
Actualmente 3109 registros
➡ Canal de YouTube (tutorial)

https://ciane.net/id=2790

Creado el : 26 Nov 2017
Alterado em : 26 Nov 2017

➡ Editar este registro
¡Sólo siga este enlace si tiene una contraseña de editor!

Ficha bibliográfica (sin autores) :

A critical appraisal of the misoprostol removable, controlled-release vaginal delivery system of labor induction - International Journal of Women’s Health - Vol. 7 - p.889-899

Autores :

Patte, C.; Deruelle, P.

Año de publicación :

2015

URL(s) :

https://www.scopus.com/inward/record.uri?eid=2-s2.…
https://doi.org/10.2147/IJWH.S62372

Résumé (français)  :

Abstract (English)  :

Background: Induction of labor is a major issue in pregnancy management. Finding strategies to increase rate and decrease time to vaginal delivery is an important goal, but maternal or neonatal safety must remain the primary objective. Misoprostol is a synthetic analogue of prostaglandin used off label to ripen the cervix and induce labor. The misoprostol vaginal insert (MVI) was designed to allow a controlled-release delivery of misoprostol (from 50 to 200 μg) with a removal tape. The objective of this review was to make a critical appraisal of this device referring to the literature. Methods: A literature search was performed in the PubMed and Cochrane databases using the keywords “vaginal misoprostol insert”. Results: Several studies compared different doses of MVI (50, 100, 150, and 200 μg) with the 10 mg dinoprostone insert. The 100 μg MVI compared with the dinoprostone vaginal insert (DVI) showed similar efficacy and no significant differences in cesarean delivery rate. MVI 200 μg compared with DVI showed a reduced time to vaginal delivery and oxytocin need but had an increased risk of uterine hyperstimulation. The rate of hyperstimulation syndrome was two to three times more frequent with the 200 μg MVI than the 100 μg. Conclusion: Current data suggest that the 100 μg MVI would provide the best balance between efficacy and safety. Further studies should be performed to evaluate this dose, especially in high-risk situations needing induction of labor. © 2015 Patte and Deruelle.

Sumário (português)  :

Resumen (español)  :

Comentarios :

Argument (français) :

Argument (English):

Argumento (português):

Argumento (español):

Palabras claves :

➡ inducción del parto ; misoprostol (Cytotec)

Autor de este registro :

Import 26/11/2017 — 26 Nov 2017